Core Viewpoint - The successful listing of Suzhou Aide Technology Development Co., Ltd. on the Beijing Stock Exchange marks a significant milestone, providing new capital support for its future development and enhancing its market confidence in the orthopedic medical device sector [1][3][10]. Listing Overview - Aide Technology raised approximately 227 million yuan through its transfer to the Beijing Stock Exchange, with plans to invest in orthopedic consumables expansion, R&D center construction, and marketing network expansion [3]. - The company issued about 29.53 million shares at a price of 7.67 yuan per share, achieving a first-day opening increase of over 220%, closing at 21.23 yuan per share, a rise of 176.79%, with a trading volume of 553 million yuan and a turnover rate of 89.61% [3]. - The successful listing not only provides capital support for further development but also strengthens the company's market position and potential for business expansion [3]. Performance Overview - In 2025, Aide Technology reported a revenue of 302 million yuan, a year-on-year increase of 9.74%, and a net profit of 77.75 million yuan, up 15.82% year-on-year [4]. - The company's operating profitability is strong, with a non-recurring net profit growth of approximately 17.99%, indicating high profit quality [4]. - Despite facing market challenges in 2023, the company adjusted its strategy and enhanced product R&D, achieving steady recovery in 2024 and 2025, with a revenue and net profit growth of about 19.07% in the first half of 2025 [4]. Product Layout - Aide Technology has focused on the research, production, and sales of orthopedic medical devices since its establishment, achieving significant success in spinal minimally invasive intervention and trauma repair [5][7]. - The company has a strong technical advantage in the spinal minimally invasive intervention field, with its vertebroplasty system ranking among the top three in the domestic market [7]. - Aide Technology is expanding its product layout into trauma repair and sports medicine, continuously investing in R&D to enrich its product line and aiming to become a comprehensive solution provider in the orthopedic medical device sector [7]. Development History - Since its establishment in 2006, Aide Technology has undergone multiple technological innovations and market breakthroughs, evolving from a small-scale enterprise focused on imitating imported products to a leading company in the domestic orthopedic medical device industry [8][9]. - The company's development history reflects its deep accumulation in the orthopedic medical device field and its adaptability to changing market conditions [9]. Conclusion - The successful transfer to the Beijing Stock Exchange provides Aide Technology with broader capital market resources and injects new vitality into its future development [10]. - With ongoing capital support, the company is expected to enhance its brand influence and pursue higher-level development, anticipating broader growth opportunities in domestic and international markets as it expands its product line and improves its technology [10].

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase exceeding 15% relative to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 items across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 93.28 million yuan, 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. - The company's gross margin is expected to be 62.45%, 57.80%, 58.05%, and 58.90% from 2022 to 2025 [50]. Business Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium-sized Enterprises" [3][28]. Competitive Position - The company ranks third among domestic manufacturers of spinal vertebral body shaping systems and sixth among spinal implant manufacturers [3][28]. - Aide Technology has a well-established national sales network and a strong communication mechanism with hospitals and orthopedic surgeons, enhancing product recognition and market penetration [5][35]. Investment Analysis - The company is positioned to benefit from the ongoing trend of centralized procurement in the industry, which is expected to normalize pricing and enhance market opportunities [4][36]. - The company’s revenue from non-procurement products is growing, helping to offset declines in procurement product revenues [47]. Use of Proceeds - The company plans to use the proceeds from its public offering for expanding orthopedic consumables production, building a research center, and enhancing its marketing network [53][54].

Investment Rating - The report suggests a focus on the company, with a recommendation to pay attention to its competitive position in the orthopedic surgical solutions market [4][42]. Core Insights - The company, Aide Technology, specializes in orthopedic consumables and has a projected net profit of 77.75 million yuan for 2025, reflecting a year-on-year increase of 15.82% [4][39]. - The company plans to use the funds raised from its IPO for expanding production capacity, building a research center, and developing a marketing network, which is expected to enhance sales scale and market share [12][14]. - The orthopedic medical device market in China is projected to reach 24.6 billion yuan by 2024, with significant growth in various segments such as spinal implants and trauma devices [42][50]. Company Overview - Aide Technology was established in 2006 and focuses on the research, production, and sales of orthopedic medical devices, including spinal, trauma, and sports medicine products [14][39]. - The company holds 110 patents and has several core products certified by the EU CE authority [14][39]. - The sales model primarily relies on distributors, with the top five customers accounting for 31.87% of total sales in the first half of 2025 [35][36]. Financial Performance - Revenue is projected to grow from 262 million yuan in 2023 to 302 million yuan in 2025, with a compound annual growth rate (CAGR) of 2% from 2022 to 2025 [39]. - The gross margin is expected to decline slightly from 62.45% in 2022 to 58.90% in 2025, while the net profit margin is projected to decrease from 32.70% to 25.85% over the same period [39][41]. Industry Insights - The orthopedic medical device industry is rapidly growing, with the market for orthopedic implants expected to reach 24.6 billion yuan by 2024 [42][50]. - The spinal implant market specifically is projected to grow to 7.2 billion yuan in 2024, despite a temporary decline due to national procurement policies [46][48]. - The trauma implant market is also expected to recover, reaching 3.9 billion yuan in 2024, following a downturn in previous years [52].